J&J fingers third party for cancer drug shortage; Arkansas surrenders death-penalty drug from U.K. source

> Johnson & Johnson has warned of imminent shortages of the cancer drug Doxil, manufactured by a unit of Boehringer Ingelheim. Story

> Arkansas joins other death-penalty states in surrendering its supply of sodium thiopental obtained from London-based Dream Pharma. Article

> European manufacturers are increasingly relying on 2D barcodes combined with advanced code reading technology to achieve required levels of traceability. Item 

> Drug companies are threatening to delay listing their products with the Australian pharmaceutical benefits scheme to protest changes in how it selects drugs. Story

> Catalent Pharma's legal leader Sam Khichi brings traditional manufacturing and supply chain techniques Lean Six Sigma to his department, leveraging the strength of collective experience via coaching, collaborating and continuous improvement. Report

> CMO Laureate Biopharmaceutical Services has signed a multi-year development and manufacturing agreement with a leading generics-maker to produce a biosimilar product.  Release

>"Soaring demand, improving standards of manufacturing facilities, and rising cost pressure" on drugmakers are expected to push the global contract manufacturing market to $34 billion by 2013, rising from $22.5 billion in 2009, says industry-watcher RNCOS. Release

> JHP Pharmaceuticals will produce clinical batches of a drug used in the treatment of heart failure for an unnamed biotech company. JHP release

> A state-owned pharmaceutical company is not the answer to providing cheaper medicines in South Africa, where the ruling party is considering the idea, says Pharma Dynamics CEO Paul Anley. Story

Suggested Articles

Lonza CEO Marc Funk is leaving for "personal reasons" after less than a year in the top job. 

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.